6 Pengelolaan Medik Kanker KL-AmiA,DrSpPD (1)
-
Upload
henry-fuji-antoni -
Category
Documents
-
view
20 -
download
3
Transcript of 6 Pengelolaan Medik Kanker KL-AmiA,DrSpPD (1)
Medical Team (teamwork) Standard Facility Standard Protocol
Medical Record
Patient
Better Communication Unity of work rhythm
Minimal mistakeMaximal patient service
MANAGEMENT OF CANCER PATIENT
Patient Doctor
Other doctors (consultant)
Cytopathologist
Radiologist
Laboratory
MANAGEMENT OF CANCER PATIENT
diagnose and treatment patient depend on one clinician only
The Relative Frequency of Head & Neck CarcinomaThe Relative Frequency of Head & Neck Carcinoma
Nasal sinuses (4%)
Oral Cavity (55%)
Larynx (25%)Hypopharynx (5%)
Oropharynx (10%)
Nasopharynx (1%)
(Skeel RT,et.al 2000)
TERAPI DENGAN BAHAN KIMIA (HORMON/SITOSTATIKA) YANG DAPAT MENGHAMBAT PERTUMBUHAN SEL KANKER
ADJUVANT setelah operasiNEOADJUVANT sebelum radiasi atau operasiPRIORITAS UTAMARADIOSENSITIZER sebelum atau bersamaan radiasi
1. Mencapai kesembuhan ( kuratif =CURE )2. Mencapai masa bebas penyakit (DFI) yang lebih lama3. Memperbaiki kualitas hidup (SURVIVAL)4. Memperkecil masa tumor sebelum operasi (neoadjuvant) mempermudah operasi
KANKER KELENJAR
(LIMFOMA MALIGNA)
KEMOTERAPIPRIORITAS UTAMA(tanpa harus operasi)
KURATIF
PROBLEM PENANGANAN
Bedah : deformitas & fungsi kosmetik Radiasi : ES (xerostomia, mucositis/stomatitis, disfagi, nekrosis, infeksi) disfungsi
Kemoterapi : ES (mucositis/stomatitis,infeksi)
PEMEILIHAN TERAPI HARUSMEMPERTIMBANGKAN KOMPLIKASI DARI
SETIAP MODAL TERAPI
Oncology aspect
Patients & family aspect
Outcome & Side Effect Monitoring
Oncology Aspect
Diagnose:- pathology :* morphologic class : adenoCa ? * histologic grade * pattern of invasion - tumor biology ? : CD20, Bcl2, p53
c-KIT(CD117), EGFR 1, Her2, EBV ?, IgA
Diagnose: Clinical Staging
Medical Status: Risk group - Anamnesa (co-morbid) - Physic, Laboratory, ECG, Radiology - Performance status (Karnosfky-ECOG)
Mechanism chemotherapy in cellular level Reduction of tumor after Chemotherapy Rational , patient financial ?
Cell Cycle mechanism
Doubling Time
Check point controle mechanism
Target of Actions of drugs( Phase specificity ? / Non phase ?)
2.Tumor cell Apoptosis
Mechanisme of Actions
Mitochondrial pathway (Bcl2 family,p53)
Death receptor pathway (Fas-FasL, caspase family of protein)
1.Tumor cell proliferation
( influence on the response to chemotherapy )
MG2
G1S
Bleomycin
5 Fudrara C6-Hydroxyurea
5 FUMETHOTREXATE
6-Thioguanine
6-Marcaptopurine
Mytomycin
Actinomycin D
Hydrocortisone Chalones
5 FU
VinblastineVincristineColchicineGriseofulvin
Differentiation
Phleomycin
Cyclophosphamide
Purin antagonis
Hydroxy urea
Actinomycin
Cyclophosphamide
5 Fudr .5FU, Ara C. Mitomycin,Doxorubicin Thioguanine
18-30h6-20h
0,5-1h
0.5-1h
2-10h
Doxorubicin
Alkylating agent, Antimetabolic, Mitotic inhibitor, Antibiotic
No response Early recurrence Late recurrence
Tumor detectable(clinically)
Long-term Remission Not palpable
Immune resistanceof host
(humoral&cellular)
Induction Consolidation Maintenance Cure
1012
109
106
103
(1kg)
(1 g)
(1 mg)
Number ofTumor cell
Tumor invisible(Remission)
(1 úg)
Patients & family Aspect
Information about : - indication chemotherapy - regimen & cycle of Chx - Side effect of drug - living with chemotherapy - informed consent
Outcome & Side Effect Monitoring Aspect
SurvivalObjective & Subjective Outcome
Diagnose & management
Outcome Side Effect
1. Onset of SE : - Immediately ( < 1 Hour post Chemotx) Anaphylaxsis - early (1- 48 hours ) Nausea-Vomiting profuse - delayed (2 days -2 months ) leucopenia - Late (after 2 months ) myopathy, neuropathy
2.Organ Target : CNS, Cardiovascular, Respiratory, Gastroentestinal System
3.Level/degree of SE (IUCC,WHO, ECOG) : - grade 0-2 : tolerable ( safety enough ) - grade 3 (severe) : must be alert (Yellow light), need treatment ± - grade 4 (life threatening) : Hazard, early and adequate treatment
DIAGNOSE of Side Effect
PHARMACOLOGYWhen Side effect become: NADIR point (degree of SE)Onset of SE, Specificity of organ target
MANAGEMENT of Side Effect
Anticipation & PreventionDose related side effect monitoringEarly treatment of side effect
SIDE EFFECT MONITORING
PROFILE EPISODE of FEBRIL NEUTROPENI SELAMA KEMOTERAPI
Chemotherapy day
Chemotherapy day
nadir1 6 11 16 21 26
Hiperpigmentation (Fluorouracili )
Emetogenic potency of cytostatic drugs
• Weak :• mitomycin, mitoxantron, ifosfamid, 5 FU,
bleomycin,etoposide,melphalan, gemcitabin• Moderate :
cyclophosphamide,anthracyclines,cytarabin,carboplatin,taxanes,irinotecan,topotecan
• Strong : cisplatin,dacarbazine,dactinomycin,any high dose therapy
Management Side Effect
1. ANTIDOTUM to specific agent : - Antidotum of MTX : Calcium leucovorin, Ca Lefofolinat - Cardiomyopathy prophylaxis – Doxorubicin > 450 mg/m2 * Dexrazosane 10 mg – Doxorubicin 1 mg
2. Dose modification : - Toxicity grade 3 and 4 : decrease dose 25% - 50%
3. Supportive Drugs : - Haemopoetic GF : G-CSF, GM-SF, IL-3, Epo - Component Blood transfuse - Selective antibiotic
4. Sterile Room technology
TREATMENT of FEBRIL NEUTROPENI SELAMA KEMOTERAPI
Empiric antibacterial
Empiric antibacterial
Chemotherapy day
Chemotherapy day
nadir
G-CSFSterile room
1.Objective Response Evaluation2.Subjective Response Evaluation(3). Survival
CANCER OUTCOME of TREATMENT
OBJECTIVE RESPONSE EVALUATIONS
1. TUMOR SIZE : - Complete remission (CR) - Partial remission (PR) - No Changes (Stable Disease = St D) - Progressive Disease (PD)
2. Marker Tumour : - CEA, CA15-3, MCA Breast Ca - CEA, CA19-9 Pancreas Ca, Colorectal Ca - HCG Chorio Ca - PSA Prostat Ca
3. Objective-Qualitative : - Change of Clinical sign : Brain Ca-neurology sign
Treatment % 5-Year Survival
RT without salvage <30
RT with salvage ±40
Concurrent CT + RT 50-55
Sequential CT RT 50-55
RTCT 50-55
CT + RT CT 75
CTCT + RT >90CT = chemotherapy , RT = radiotherapy
Stage IV Nasopharyngeal Cancer:
Change in Overall Survival, 1980-2000
(Muhyi Al-Sarraf,2002)
Tepat indikasi : kemoterapi tepat dipilih berdasar titik tangkap kerjanya berdasar patogenesis kanker sehingga dapat tercapai tujuan : 1.kuratif 2.mencapai bebas penyakit (DFI) yang lebih lama 3.neoadjuvant (mengecilkan volume tumor preoperasi- down staging) 4.mempertahankan atau meningkatkan quality of life (terapi paliatif)
RINGKASAN :
Tepat cara pemberian obat : oral, IV, bolus, infusion dsb yang penting : penderita nyaman , tidak takut dan dengan kesadaran sendiri ingin melanjutkan kemoterapi Tepat monitoring efek obat : - penilaian hasil / respons terapi - kemampuan hidup (quality of life) dan - efek samping obat
Tepat jenis obat : sebaiknya lebih spesifik, selektif, mem- punyai Response rate tinggi, established, dan dapat dijangkau oleh penderita
Tepat dosis obat : sesuai Maximum Tolerated Dose ( Risk group )
RESUME :
Better Communication Unity of work rhythmMinimal mistakeMaximal patient service
Oncology aspect Patients & family aspect
Outcome & Side Effect Monitoring
Diagnose:- pathology - biology cell type ?
Diagnose: Staging
Medical Status: Risk group
Information about : - indication chemotherapy - regimen & cycle of Chx - Side effect of drug - living with chemtherapy - informed consent
SurvivalObjective & Subjective Outcome
Side Effect : Diagnose & management
RESUME :
TERIMA KASIH
Regimens of Chemotherapy
Regimen Response
Regimen Doses RR
Methotrexate 40-60 mg/m2/weekly 25-50%Bleomycin 10-30 mg/m2/weekly 15-25%Cisplatin 4-60 mg/m2/3 weeks 25%Carboplatin 360-400 mg/m2/4 weeks 25% divided in 3 daily5 FU 500-750 mg/m2/d1-5/ 15% 4 weeksAnthracyclines 50 mg/m2/3 weeks 25%Ifosfamide 2 g/m2/3-4 weeks 28-42%Taxan(P) 250 mg/m2/3 weeks 40%Gemcitabine 1250 mg/m2/d1,8/3 weeks ??
(Skeel RT,et.al 2000)